Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
February 1, 2024 updated by: Reata, a wholly owned subsidiary of Biogen
A Randomized Phase I/II Study With Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer
This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in patients with unresectable pancreatic cancer.
Study Overview
Status
Terminated
Conditions
Detailed Description
Phase I will be conducted to determine the MTD of RTA 402 (administered orally Days 1-21 or Days 1-28 of a 28-day cycle) in combination with gemcitabine (1000 m/m2). Gemcitabine will be administered as an intravenous infusion on Days 1, 8, and 15 of each 28-day cycle.
The phase II portion of the study will be randomized, and double-blinded. Phase II will utilize the RTA 402 MTD determined in Phase I; Arm 1 will consist of gemcitabine + RTA 402. RTA 402 capsules will administered orally Days 1-21 of each 28-day cycle (or Days 1-28 if appropriate, based on phase I results); gemcitabine (1000 mg/m2) will be administered as an intravenous infusion on Days 1, 8, and 15 of each 28-day cycle in each Arm. Arm 2 will consist of gemcitabine + placebo, placebo capsules will be taken orally Days 1-21 of each 28-day cycle (or Days 1-28 if appropriate, based on phase I results). Both treatment arms are 4-weeks in length.
The study was conceived with both a Phase I and Phase II portion as described above; however, only the Phase I portion was completed. The trial was terminated in 2009 before the Phase II portion could begin.
Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Denver, Colorado, United States
- Rocky Mountain Cancer Center (US Oncology)
-
-
Florida
-
Ocoee, Florida, United States
- Cancer Centers of Florida (US Oncology)
-
-
Indiana
-
Indianapolis, Indiana, United States
- Central Indiana Cancer Centers (US Oncology)
-
-
Texas
-
Dallas, Texas, United States, 75246
- Sammons Cancer Center (US Oncology)
-
-
Washington
-
Vancouver, Washington, United States
- Northwest Cancer Specialist- Vancouver Cancer Specialist (US Oncology)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Phase I patients should have treatment naïve pancreatic cancer; however , Phase I patients who have had 1 prior regimen consisting of adjuvant chemo-radiation or adjuvant gemcitabine - as defined within the NCCN guidelines may be enrolled. Phase II patients must have metastatic disease (Stage IV only).
- Karnofsky performance status of >70%
- Adequate liver function. (total bilirubin ≤ 1.5 mg/dL and AST(SGOT) and ALT(SGPT) of < 2.5 ULN ( ≤ 5 ULN for Phase II patients with liver metastases), Serum Creatinine < 1.5 ULN
- Adequate bone marrow function as documented by the following laboratory test results within 14 days of starting therapy. platelets ≥100,000/mm3, absolute neutrophil count (ANC) ≥1500/mm3, hemoglobin ≥9.0 g/dL, white blood cell (WBC) count ≥3000 /mm3
- Practice effective contraception during the entire study period.
- Life expectancy of more than 3 months.
- Able and willing to sign the informed consent form.
- Willing and able to self-administer orally and document all doses of RTA 402 ingested.
Exclusion Criteria:
- Prior treatment for current malignancy outside of the adjuvant setting for Phase I
- Inability to swallow tablets or capsules
- Active brain metastases or primary central nervous system (CNS) malignancies. (Patients with a previously treated brain metastasis may be included.)
- Active second malignancy
- Ten percent or greater weight loss over the 6 weeks before study entry.
- Pregnant or breast feeding
- Clinically significant illnesses which could compromise participation in the study, including, but not limited to: Uncontrolled diabetes; Active or uncontrolled infection; Acute or chronic liver disease; Confirmed diagnosis of Human immunodeficiency virus (HIV) infection; Uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia.
- Psychiatric illness that would limit compliance with study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Phase 1 Cohort 1
Bardoxolone methyl 150 mg/day x 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
Bardoxolone methyl capsules (150 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (300 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (150 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (200 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (250 mg/day) for 28 days
Other Names:
Bardoxlone methyl capsules (300 mg/day) x 28 days
Other Names:
Bardoxolone methyl capsules (350 mg/day) x 28 days
Other Names:
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
Other Names:
|
|
Experimental: Phase 1 Cohort 2
Bardoxolone methyl 300 mg /day for 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
Bardoxolone methyl capsules (150 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (300 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (150 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (200 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (250 mg/day) for 28 days
Other Names:
Bardoxlone methyl capsules (300 mg/day) x 28 days
Other Names:
Bardoxolone methyl capsules (350 mg/day) x 28 days
Other Names:
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
Other Names:
|
|
Experimental: Phase 1 Cohort 3
Bardoxolone methyl 150 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
Bardoxolone methyl capsules (150 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (300 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (150 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (200 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (250 mg/day) for 28 days
Other Names:
Bardoxlone methyl capsules (300 mg/day) x 28 days
Other Names:
Bardoxolone methyl capsules (350 mg/day) x 28 days
Other Names:
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
Other Names:
|
|
Experimental: Phase 1 Cohort 4
Bardoxolone methyl 200 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
Bardoxolone methyl capsules (150 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (300 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (150 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (200 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (250 mg/day) for 28 days
Other Names:
Bardoxlone methyl capsules (300 mg/day) x 28 days
Other Names:
Bardoxolone methyl capsules (350 mg/day) x 28 days
Other Names:
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
Other Names:
|
|
Experimental: Phase 1 Cohort 5
Bardoxolone methyl 250 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
Bardoxolone methyl capsules (150 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (300 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (150 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (200 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (250 mg/day) for 28 days
Other Names:
Bardoxlone methyl capsules (300 mg/day) x 28 days
Other Names:
Bardoxolone methyl capsules (350 mg/day) x 28 days
Other Names:
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
Other Names:
|
|
Experimental: Phase 1 Cohort 6
Bardoxolone methyl 300 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
Bardoxolone methyl capsules (150 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (300 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (150 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (200 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (250 mg/day) for 28 days
Other Names:
Bardoxlone methyl capsules (300 mg/day) x 28 days
Other Names:
Bardoxolone methyl capsules (350 mg/day) x 28 days
Other Names:
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
Other Names:
|
|
Experimental: Phase 1 Cohort 7
Bardoxolone methyl 350 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
Bardoxolone methyl capsules (150 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (300 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (150 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (200 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (250 mg/day) for 28 days
Other Names:
Bardoxlone methyl capsules (300 mg/day) x 28 days
Other Names:
Bardoxolone methyl capsules (350 mg/day) x 28 days
Other Names:
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
Other Names:
|
|
Experimental: Phase 2 Cohort 1
Bardoxolone methyl maximum tolerated dose(as determined in the Phase 1 portion of the study)/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
Bardoxolone methyl capsules (150 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (300 mg/day) for 21 days
Other Names:
Bardoxolone methyl capsules (150 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (200 mg/day) for 28 days
Other Names:
Bardoxolone methyl capsules (250 mg/day) for 28 days
Other Names:
Bardoxlone methyl capsules (300 mg/day) x 28 days
Other Names:
Bardoxolone methyl capsules (350 mg/day) x 28 days
Other Names:
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
Other Names:
|
|
Placebo Comparator: Phase 2 Cohort 2
Placebo capsules/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
|
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Other Names:
Placebo capsules x 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Phase I - To determine the maximum tolerated dose (MTD) of RTA 402 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Time Frame: End of trial
|
End of trial
|
|
Phase II - To determine if treatment with RTA 402 in combination with gemcitabine can increase the progression-free survival versus gemcitabine plus placebo in patients with unresectable metastatic pancreatic cancer.
Time Frame: End of Trial
|
End of Trial
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Phase I - To document any preliminary antitumor activity of RTA 402 in this patient population.
Time Frame: End ofTrial
|
End ofTrial
|
|
Phase I - To characterize the pharmacokinetics (PK) of RTA 402 in this population.
Time Frame: End of Trial
|
End of Trial
|
|
Phase II - To determine the overall response rate in patients treated with RTA 402 + gemcitabine and in patients treated with gemcitabine + placebo.
Time Frame: End of Trial
|
End of Trial
|
|
Phase II - To determine the 1-year survival in this patient population.
Time Frame: End of Trial
|
End of Trial
|
|
Phase II - To determine the toxicities of these regimens.
Time Frame: End of Trial
|
End of Trial
|
|
Phase II - To determine the changes in quality of life (Functional Assessment of Chronic Illness Therapy (Fatigue), [FACIT-F]).
Time Frame: End of Trial
|
End of Trial
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2007
Primary Completion (Actual)
November 1, 2009
Study Completion (Actual)
November 1, 2009
Study Registration Dates
First Submitted
September 12, 2007
First Submitted That Met QC Criteria
September 12, 2007
First Posted (Estimated)
September 14, 2007
Study Record Updates
Last Update Posted (Actual)
February 2, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Gemcitabine
Other Study ID Numbers
- 402-C-0702
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Neoplasms
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Celgene CorporationCompletedPancreatic Adenocarcinoma | Resectable Pancreatic CarcinomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Laser Tissue Welding, Inc.National Cancer Institute (NCI); CHI St. Luke's Health, TexasCompletedPancreatic Neoplasms | Pancreatic Adenocarcinoma | Pancreatic Cyst | Pancreatic Neuroendocrine Tumor | Pancreatic Polypeptide Tumor | Pancreatic Pseudocyst | Pancreatic Glucagonoma | Pancreas Injury | Pancreatic Cystadenoma | Pancreatic Tumor, Benign | Pancreas; Insulinoma | Pancreatic Teratoma | Pancreatic Vipoma and other conditionsUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingLocally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic NeoplasmChina
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
Clinical Trials on Bardoxolone methyl
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenWithdrawnDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenCompletedHealthy | Hepatic ImpairmentUnited States
-
Reata, a wholly owned subsidiary of BiogenWithdrawnDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenTerminatedDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenTerminatedChronic Kidney Diseases | Autosomal Dominant Polycystic Kidney | Alport SyndromeUnited States, France, Australia, Japan, Spain, Puerto Rico
-
Reata, a wholly owned subsidiary of BiogenCompletedDiabetic NephropathyUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedDiabetes Mellitus, Type 2 | Renal Insufficiency, ChronicUnited States
-
NYU Langone HealthReata Pharmaceuticals, Inc.Completed